Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


23.12.2018

3 Ann Thorac Surg
1 BMC Cancer
1 Cancer
2 Clin Lung Cancer
1 Eur J Cancer
1 Eur J Cardiothorac Surg
2 Hum Pathol
1 Int J Radiat Oncol Biol Phys
2 J Thorac Cardiovasc Surg
1 J Thorac Oncol
9 Lung Cancer
1 Oncogene
1 Oncol Rep
1 PLoS Genet
1 PLoS One
2 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Thorac Surg

  1. KAI Y, Tsutani Y, Ito M, Mimura T, et al
    Metachronous Lung Cancer After Pleurectomy/Decortication.
    Ann Thorac Surg. 2019;107:e1-e3.
    PubMed     Text format     Abstract available

  2. ZHAO Y, Wang W, Liang H, Jeffrey Yang CF, et al
    The Optimal Treatment for Stage IIIA-N2 Non-small-cell Lung Cancer: A Network Meta-analysis.
    Ann Thorac Surg. 2018 Dec 14. pii: S0003-4975(18)31821.
    PubMed     Text format     Abstract available

  3. HOEIJMAKERS F, Heineman DJ, Beck N, Klamer J, et al
    Mediastinoscopy for staging of Non-Small Cell Lung Cancer: surgical performance in the Netherlands.
    Ann Thorac Surg. 2018 Dec 14. pii: S0003-4975(18)31827.
    PubMed     Text format     Abstract available


    BMC Cancer

  4. REMEN T, Pintos J, Abrahamowicz M, Siemiatycki J, et al
    Risk of lung cancer in relation to various metrics of smoking history: a case-control study in Montreal.
    BMC Cancer. 2018;18:1275.
    PubMed     Text format     Abstract available


    Cancer

  5. NAZHA B, Owonikoko TK
    The clinical conundrum of managing relapsed small cell lung cancer.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31849.
    PubMed     Text format    


    Clin Lung Cancer

  6. SONG Z, Wang H, Yu Z, Lu P, et al
    De Novo MET Amplification in Chinese Patients With Non-Small-Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study.
    Clin Lung Cancer. 2018 Nov 26. pii: S1525-7304(18)30303.
    PubMed     Text format     Abstract available

  7. KATSUMATA S, Aokage K, Nakasone S, Sakai T, et al
    Radiologic Criteria in Predicting Pathologic Less Invasive Lung Cancer According to TNM 8th Edition.
    Clin Lung Cancer. 2018 Nov 15. pii: S1525-7304(18)30297.
    PubMed     Text format     Abstract available


    Eur J Cancer

  8. VON PAWEL J, Bordoni R, Satouchi M, Fehrenbacher L, et al
    Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.
    Eur J Cancer. 2018;107:124-132.
    PubMed     Text format     Abstract available


    Eur J Cardiothorac Surg

  9. DENG HY, Zha P, Zhou Q
    Sarcopenia: an unneglectable nutritional status for patients with surgically treated non-small-cell lung cancer.
    Eur J Cardiothorac Surg. 2018 Dec 18. pii: 5251904. doi: 10.1093.
    PubMed     Text format    


    Hum Pathol

  10. INAGUMA S, Lasota J, Wang Z, Czapiewski P, et al
    Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
    Hum Pathol. 2018;71:1-7.
    PubMed     Text format     Abstract available

  11. BOLAND JM, Maleszewski JJ, Wampfler JA, Voss JS, et al
    Pulmonary invasive mucinous adenocarcinoma and mixed invasive mucinous/nonmucinous adenocarcinoma-a clinicopathological and molecular genetic study with survival analysis.
    Hum Pathol. 2018;71:8-19.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys


  12. Erratum to: Kasmann L, Manapov F. Immune Checkpoint Inhibition Combined With Intracranial Stereotactic Radiation Therapy in Non-Small Cell Lung Cancer: Is There an Increased Rate of Radionecrosis or Not? Int J Radiat Oncol Biol Phys 2018;102:465.
    Int J Radiat Oncol Biol Phys. 2019;103:286.
    PubMed     Text format    


    J Thorac Cardiovasc Surg

  13. DAVID EA, Andersen SW, Beckett LA, Melnikow J, et al
    Survival benefits associated with surgery for advanced non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2018 Nov 14. pii: S0022-5223(18)32941.
    PubMed     Text format     Abstract available

  14. GUCKENBERGER M, Aerts JG, Van Schil P, Weder W, et al
    The American Society of Clinical Oncology-endorsed American Society for Radiation Oncology Evidence-Based Guideline of stereotactic body radiotherapy for early-stage non-small cell lung cancer: An expert opinion.
    J Thorac Cardiovasc Surg. 2019;157:358-361.
    PubMed     Text format    


    J Thorac Oncol

  15. YATABE Y, Dacic S, Borczuk AC, Warth A, et al
    Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.
    J Thorac Oncol. 2018 Dec 17. pii: S1556-0864(18)33514.
    PubMed     Text format     Abstract available


    Lung Cancer

  16. HORNE ZD, Richman AH, Dohopolski MJ, Clump DA, et al
    Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers.
    Lung Cancer. 2018;115:1-4.
    PubMed     Text format     Abstract available

  17. ZHANG L, Belani CP, Zhang PH, Wang X, et al
    Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial.
    Lung Cancer. 2018;115:121-126.
    PubMed     Text format     Abstract available

  18. ZHU YC, Wang WX, Xu CW, Song ZB, et al
    EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report.
    Lung Cancer. 2018;115:131-134.
    PubMed     Text format     Abstract available

  19. ONO A, Isaka M, Serizawa M, Omae K, et al
    Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer.
    Lung Cancer. 2018 Dec 5. pii: S0169-5002(18)30691.
    PubMed     Text format     Abstract available

  20. NAKAMURA H, Ichikawa T, Nakasone S, Miyoshi T, et al
    Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions.
    Lung Cancer. 2018;115:56-63.
    PubMed     Text format     Abstract available

  21. JIANG J, Wu X, Tong X, Wei W, et al
    GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
    Lung Cancer. 2018;115:5-11.
    PubMed     Text format     Abstract available

  22. MIURA Y, Kaira K, Sakurai R, Sunaga N, et al
    High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin.
    Lung Cancer. 2018;115:42-48.
    PubMed     Text format     Abstract available

  23. MINARI R, Bordi P, Del Re M, Facchinetti F, et al
    Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
    Lung Cancer. 2018;115:21-27.
    PubMed     Text format     Abstract available

  24. GALLI G, Corrao G, Imbimbo M, Proto C, et al
    Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review.
    Lung Cancer. 2018;115:135-142.
    PubMed     Text format     Abstract available


    Oncogene

  25. WIESWEG M, Kasper S, Worm K, Herold T, et al
    Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer.
    Oncogene. 2018 Dec 19. pii: 10.1038/s41388-018-0634.
    PubMed     Text format     Abstract available


    Oncol Rep

  26. LIU J, Wang D, Meng X, Sun X, et al
    18Falfatide positron emission tomography may predict antiangiogenic responses.
    Oncol Rep. 2018;40:2896-2905.
    PubMed     Text format     Abstract available


    PLoS Genet

  27. GAO P, Wang H, Yu J, Zhang J, et al
    miR-3607-3p suppresses non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2.
    PLoS Genet. 2018;14:e1007790.
    PubMed     Text format     Abstract available


    PLoS One

  28. HU ZG, Li WX, Ruan YS, Zeng FJ, et al
    Incidence trends and risk prediction nomogram of metachronous second primary lung cancer in lung cancer survivors.
    PLoS One. 2018;13:e0209002.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  29. KAWAKAMI M, Mustachio LM, Zheng L, Chen Y, et al
    Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition.
    Proc Natl Acad Sci U S A. 2018;115:E10810-E10811.
    PubMed     Text format    

  30. OEGEMA K, Davis RL, Lara-Gonzalez P, Desai A, et al
    CFI-400945 is not a selective cellular PLK4 inhibitor.
    Proc Natl Acad Sci U S A. 2018;115:E10808-E10809.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: